scispace - formally typeset
F

Farshid Dayyani

Researcher at University of California, Irvine

Publications -  124
Citations -  4100

Farshid Dayyani is an academic researcher from University of California, Irvine. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 26, co-authored 84 publications receiving 3489 citations. Previous affiliations of Farshid Dayyani include University of Leicester & Harvard University.

Papers
More filters
Journal ArticleDOI

The Proinflammatory CD14+CD16+DR++ Monocytes Are a Major Source of TNF

TL;DR: The minor population of CD14+CD16+ monocytes are major producers of TNF in human blood, and the median fluorescence intensity for Toll-like receptor 2 cell surface protein was found 2-fold higher on CD14-CD16-DR++ monocytes, which may explain, in part, the higher Pam3Cys-induced TNF production by these cells.
Journal ArticleDOI

Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC)

TL;DR: HPV+ HNSCC are established as a separate biologic entity and Prospective trials are needed to establish the optimal therapy for HPV+ H NSCC.
Journal ArticleDOI

Resistance to BRAF Inhibition in BRAF-Mutant Colon Cancer Can Be Overcome with PI3K Inhibition or Demethylating Agents

TL;DR: It is shown that activation of the PI3K/AKT pathway is a mechanism of both innate and acquired resistance to BRAF inhibitors in BRAFV600E CRC and suggest combinatorial approaches to improve outcomes in this poor prognosis subset of patients.
Journal ArticleDOI

Selective mobilization of CD14(+)CD16(+) monocytes by exercise.

TL;DR: It is shown that in human peripheral blood the effect of exercise on the number of CD14(+)CD16(+) monocytes as determined by two-color immunofluorescence and flow cytometry shows a dramatic up to 4.8-fold increase in this type of monocyte.
Journal ArticleDOI

Steps in prostate cancer progression that lead to bone metastasis

TL;DR: Although many of these processes still need to be fully elucidated, a better understanding of the complex tumor/microenvironment interplay is slowly leading to more effective therapies for patients with prostate cancer bone metastases.